Logo
x

Search

Subscribe Now

Haemophilia A

Roche Presents Results of Hemlibra Reinforcing the Long-Term Benefits for Hemophilia A at ASH 2020

Roche Presents Results of Hemlibra Reinforcing the Long-Term Benefits for Hemophilia A at ASH 2020

  • December 7, 2020
Roche's Hemlibra Receives EU's Approval for Severe Haemophilia A without Factor VIII Inhibitors

Roche's Hemlibra Receives EU's Approval for Severe Haemophilia A without Factor VIII Inhibitors

  • March 14, 2019
Novo Nordisk Receives BLA Approval for Esperoct (turoctocog alfa pegol- N8-GP) for Patients with Haemophilia A

Novo Nordisk Receives BLA Approval for Esperoct (turoctocog alfa pegol- N8-GP) for Patients with Haemophilia A

  • February 20, 2019
Roche's Hemlibra Receives the US FDA Approval for Haemophilia A Without Factor VIII Inhibitors

Roche's Hemlibra Receives the US FDA Approval for Haemophilia A Without Factor VIII Inhibitors

  • October 5, 2018
Bayer's BAY94-9027 Receives CHMP Approval for the Treatment of Haemophilia A aged ≥12yrs.

Bayer's BAY94-9027 Receives CHMP Approval for the Treatment of Haemophilia A aged ≥12yrs.

  • September 24, 2018
Roche's Hemlibra P-III Positive results for Haemophilia A without factor VIII being published in NEJM

Roche's Hemlibra P-III Positive results for Haemophilia A without factor VIII being published in NEJM

  • August 30, 2018
Novo Nordisk Presents Results of Concizumab in P-III (explorer7) Study for the Treatment of Haemophilia A or B at ISTH 2022

    Novo Nordisk Presents Results of Concizumab in P-III (explorer7) Study for the Treatment of Haemophilia A or B at ISTH 2022

    • July 11, 2022
    Sobi and Sanofi Report Results of Efanesoctocog Alfa (BIVV001) in P-III (XTEND-1) study for the Treatment of Haemophilia A

      Sobi and Sanofi Report Results of Efanesoctocog Alfa (BIVV001) in P-III (XTEND-1) study for the Treatment of Haemophilia A

      • March 9, 2022
      Roche Presents Results of Hemlibra Reinforcing the Long-Term Benefits for Hemophilia A at ASH 2020

        Roche Presents Results of Hemlibra Reinforcing the Long-Term Benefits for Hemophilia A at ASH 2020

        • December 7, 2020
        Roche

          Roche's Hemlibra Receives EU's Approval for Severe Haemophilia A without Factor VIII Inhibitors

          • March 14, 2019
          Novo Nordisk Receives BLA Approval for Esperoct (turoctocog alfa pegol- N8-GP) for Patients with Haemophilia A

            Novo Nordisk Receives BLA Approval for Esperoct (turoctocog alfa pegol- N8-GP) for Patients with Haemophilia A

            • February 20, 2019
            Roche

              Roche's Hemlibra Receives the US FDA Approval for Haemophilia A Without Factor VIII Inhibitors

              • October 5, 2018
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.